| Date Filed | Type | Description |
| 10/06/2023 |
SC 13G/A
| BlackRock Inc. reports a 4.6% stake in NGM BIOPHARMACEUTICALS INC |
| 08/11/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/07/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/04/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/04/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 06/08/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 06/08/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/12/2023 |
4
| Guyer Shelly D (Director) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC|
Txns:
| Granted 78,407 options to buy
@ $3.69, valued at
$289.3k
|
|
| 05/12/2023 |
4
| RIEFLIN WILLIAM JL (Director) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC|
Txns:
| Granted 78,407 options to buy
@ $3.69, valued at
$289.3k
|
|
| 05/12/2023 |
4
| Hooper Suzanne Sawochka (Director) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC|
Txns:
| Granted 78,407 options to buy
@ $3.69, valued at
$289.3k
|
|
| 05/12/2023 |
4
| GOEDDEL DAVID V (10% Owner) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC|
Txns:
| Granted 78,407 options to buy
@ $3.69, valued at
$289.3k
|
|
| 05/12/2023 |
4
| PERLMUTTER ROGER M (Director) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC|
Txns:
| Granted 78,407 options to buy
@ $3.69, valued at
$289.3k
|
|
| 05/12/2023 |
4
| Ho Carole (Director) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC|
Txns:
| Granted 78,407 options to buy
@ $3.69, valued at
$289.3k
|
|
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/04/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
| 03/29/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/29/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/29/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/06/2023 |
4
| Nolan Mangini Siobhan (President and CFO) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC|
Txns:
| Granted 76,000 shares
@ $0
Granted 228,000 options to buy
@ $4.36, valued at
$994.1k
Granted 200,000 options to buy
@ $4.36, valued at
$872k
|
|
| 03/06/2023 |
4
| WOODHOUSE DAVID J (CEO) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC|
Txns:
| Granted 127,200 shares
@ $0
Granted 381,600 options to buy
@ $4.36, valued at
$1.7M
Granted 500,000 options to buy
@ $4.36, valued at
$2.2M
|
|
| 03/06/2023 |
4
| Lieu Hsiao D (SVP, Chief Medical Officer) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC|
Txns:
| Granted 53,000 shares
@ $0
Granted 159,000 options to buy
@ $4.36, valued at
$693.2k
|
|
| 03/06/2023 |
4
| CHEN JIN-LONG (Chief Scientific Officer) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC|
Txns:
| Granted 64,000 shares
@ $0
Granted 192,000 options to buy
@ $4.36, valued at
$837.1k
Granted 175,000 options to buy
@ $4.36, valued at
$763k
|
|
| 03/06/2023 |
4
| Pierce Valerie L (SVP, GC & CCO) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC|
Txns:
| Granted 49,000 shares
@ $0
Granted 147,000 options to buy
@ $4.36, valued at
$640.9k
Granted 150,000 options to buy
@ $4.36, valued at
$654k
|
|
| 03/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 02/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G
| VANGUARD GROUP INC reports a 5.5% stake in NGM Biopharmaceuticals Inc. |
| 02/03/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|